Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 17 · below the Ichimoku cloud · RSI 26 (oversold) · MACD above its signal · at its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $13.9K | 0.00% | 19.83K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LGVN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.7 | -3.4 | 92.2 | -18.3 | -9.2 | -8.9 | -0.1 | -1.7 | -61.0 | -20.1 | −57.5% | ||
| 2025 | -11.0 | -1.3 | 2.0 | 8.4 | -26.2 | 4.8 | 24.6 | -48.9 | -9.4 | 11.2 | -20.4 | -23.8 | −70.8% |
| 2024 | -60.4 | -0.9 | -39.1 | -47.4 | -35.7 | 46.4 | 94.4 | -34.8 | -4.9 | 7.7 | -1.9 | -15.6 | −87.3% |
| 2023 | 25.5 | -11.4 | -25.4 | 8.2 | 2.4 | 14.2 | -2.1 | -15.1 | -16.7 | -15.8 | -0.5 | -30.6 | −57.8% |
| 2022 | -38.1 | -9.5 | 104.1 | -27.4 | -18.5 | -27.4 | 5.1 | -23.2 | -22.7 | -2.2 | 7.2 | -17.0 | −73.3% |
| 2021 | -17.6 | -6.7 | 7.3 | 23.2 | -29.4 | -39.4 | 1.4 | -2.3 | 661.2 | -54.0 | +50.9% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Cann Leah RushDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Ascheim DeborahDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Hare Joshua MOfficer, Director and Beneficial Owner | Stock Award(Grant) at price 0.00 per share. | 286K | — |
| Aug 18, 2026 | Soffer Rock JDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Lehr Paul TGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 286K | — |
| Aug 18, 2026 | Ungaro UrsulaDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Agafonova NataliyaOfficer | Stock Award(Grant) at price 0.00 per share. | 286K | — |
| Aug 18, 2026 | Desai Arjun JjDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Hajjar Roger JosephDirector | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Aug 18, 2026 | Blass DevinChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 286K | — |
| Aug 18, 2026 | Paletta George A Jr.Director | Stock Award(Grant) at price 0.00 per share. | 36K | — |
| Apr 30, 2026 | Willard Stephen HChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 500K | — |
| Apr 30, 2026 | Lehr Paul TGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 250K | — |
| Apr 30, 2026 | Agafonova NataliyaOfficer | Stock Award(Grant) at price 0.00 per share. | 250K | — |
| Apr 30, 2026 | Locklear LisaChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 250K | — |
| Apr 30, 2026 | Blass DevinOfficer | Stock Award(Grant) at price 0.00 per share. | 250K | — |
| Mar 1, 2026 | Willard Stephen HChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 400K | — |
| Sep 30, 2025 | Paletta George A Jr.Director | Stock Award(Grant) at price 0.00 per share. | 34K | — |
| Sep 3, 2025 | Powell James NathanielChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Aug 10, 2025 | Baluch KhosoDirector | Purchase at price 0.70 per share. | 11.8K | $8.18K |
Buy / hold / sell counts
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.